Clinical Trial Update: Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on QL1206 for postmenopausal osteoporosis with high fracture risk, assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• QL1206 (denosumab)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Postmenopausal Osteoporosis | Phase 3 | Status: UNKNOWN